St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares saw a decline of 3.53%, finishing Tuesday's trading session at $6.29. A total volume of 1.27 million shares was traded. The stock has surged 157.79% in the past month, 6,344.67% over the previous three months, and 214.50% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 69.02% and 435.87%, respectively. Moreover, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have a Relative Strength Index (RSI) of 48.77.
On January 23rd, 2017, EnteroMedics announced the closing of an underwritten public offering of units for gross proceeds of $19.0 million. The offering comprised of Class A units, priced at a public offering price of $5.31 per unit, with each unit consisting of one share of common stock and one five-year warrant to purchase one share of common stock with an exercise price of $5.84 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which is convertible into 188 shares of common stock, and warrants to purchase 188 shares of common stock. See our free and comprehensive research report on ETRM at:
On Tuesday, shares in Abbott Park, Illinois headquartered Abbott Laboratories recorded a trading volume of 12.32 million shares, which was above their three months average volume of 9.13 million shares. The stock ended the session 1.85% higher at $41.77. The Company's shares have gained 9.74% in the last one month, 6.32% in the previous three months, and 9.45% on an YTD basis. The stock is trading 6.51% above its 50-day moving average and 3.96% above its 200-day moving average. Furthermore, shares of Abbott Laboratories, which manufactures and sells health care products worldwide, have an RSI of 75.29.
On January 25th, 2017, Alere Inc. announced that the European Commission has granted clearance for Abbott Laboratories to acquire Alere. On February 01st, 2016, Alere has entered into a definitive agreement under which Abbott will acquire Alere for $56 per common share in cash.
On January 26th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $48 a share to $46 a share. ABT free research report PDF is just a click away at:
Shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. closed at $24.06, climbing 0.88% from the last trading session. The stock recorded a trading volume of 6.52 million shares. The Company's shares have advanced 10.88% in the last one month, 8.92% over the previous three months, and 11.23% on an YTD basis. The stock is trading 9.58% and 6.11% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 73.30.
On January 03rd, 2017, Boston Scientific announced that it will webcast its conference call discussing financial results for Q4 2016 on February 02nd, 2017, at 8:00 a.m. ET. The Company will issue a news release announcing financial results on February 02nd, 2017, prior to the conference call. Sign up for your complimentary report on BSX at:
At the closing bell yesterday, shares in Dublin, Ireland headquartered Medtronic PLC ended 1.81% higher at $76.02. A total volume of 7.81 million shares was traded, which was above their three months average volume of 7.04 million shares. The stock has advanced 6.26% in the last one month and 6.72% since the start of this year. The Company's shares are trading above their 50-day moving average by 3.12%. Furthermore, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 63.39.
On January 03rd, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight', with a target price of $77 per share. Register for free on Stock-Callers.com and download the latest research report on MDT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA